



Extension Seminar in Clinical Trials

Program

Self-paced learning package: available from Friday 22 March 2024

| Presentation | Learning objectives | Presenter |
|--|---|---|
| <p>Clinical trials manufacturing: considerations for TGA GMP licenced vs. non-licenced facilities and international perspectives on clinical trials manufacturing</p> | <ul style="list-style-type: none"> • Compare the standards for GMP licenced manufacturing vs non-GMP licenced manufacturing • Justify when you need a GMP licence to manufacture clinical trials • Discuss GMP training essentials • Identify the special considerations for advanced therapeutics • Explore and apply data from international databases • Explain the process and importance of being prepared for a GMP audit • Explain the variables in international regulations and what is and is not appropriate in Australia | <p>Kerry Watts, Senior Project and Policy Officer, Advanced Therapeutics, Office for Health and Medical Research, NSW Ministry of Health, NSW</p> <p>Katrina Orr, Senior Teletrial Pharmacist, Australian Teletrial Program - Western Australia, WA Country Health Service, Department of Research and Innovation, WA</p> |
| <p>National Clinical Trials Framework</p> | <ul style="list-style-type: none"> • Explain what the National Clinical Trials Governance Framework is and how it applies to health service organisations • Discuss the history of the Clinical Trials Governance framework • Describe how the clinical trials governance framework applies to pharmacy • Identify the key areas of focus when coming up for accreditation | <p>Liam King, National Research Lead and Cancer Care Coordinator – Pharmacy, Ramsay Health, Brisbane, Qld</p> |
| <p>Human Research Ethics Committee (HREC) membership: how to review a submitted protocol and IB</p> | <ul style="list-style-type: none"> • Overview information and essential documents provided in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) • Describe the purpose and expected content of an Investigator’s Brochure (IB) • Outline requirements for a clinical trial protocol • Explain key considerations, critical elements and best practices to facilitate a thorough and effective HREC review process for protocols and IBs | <p>June Challen, Specialist Pharmacist Investigational Drugs, SA Health, Adelaide, SA</p> |



Program

Live seminar: Saturday 4 May 2024

All times listed are in AEST

| Time (AEST) | Session |
|-------------|--|
| 0945-1000 | Online login and registration available |
| 1000-1005 | Welcome and introductions |
| 1005-1015 | <p>Review and open Q&A Liam King, National Research Lead and Cancer Care Coordinator – Pharmacy, Ramsay Health, Brisbane, Qld</p> |
| 1015-1130 | <p>Interactive session: Growing your clinical trials unit Led by: Romana Cecchele, Senior Pharmacist – Investigational Drug Unit, Royal Prince Alfred Hospital, Sydney, NSW</p> <p>Tutors: Eugenia Hong, Romana Cecchele, Liam King, June Challen</p> |
| 1130-1150 | Break |
| 1150-1250 | <p>Interactive session: Budgeting and invoicing Led by: Eugenia Hong, Clinical Trials Pharmacy Manager, Pharmacy Department, Royal Melbourne Hospital, Melbourne, Vic</p> <p>Tutors: Eugenia Hong, Romana Cecchele, Liam King, June Challen</p> |
| 1250-1330 | <p>Electronic pharmacy files and online accountability Janet Gaon, Senior Clinical Trials and Application Specialist Pharmacist, Chris O'Brien Lifehouse, Sydney, NSW</p> |
| 1330-1345 | Break |
| 1345-1445 | <p>Interactive session: Clinical trials and Good Manufacturing Practice Kerry Watts, Senior Project and Policy Officer, Advanced Therapeutics, Office for Health and Medical Research, NSW Ministry of Health, NSW Katrina Orr, Senior Teletrial Pharmacist, Australian Teletrial Program - Western Australia, WA Country Health Service, Department of Research and Innovation, WA</p> <p>Tutors: Kerry Watts, Katrina Orr, Liam King, June Challen</p> |
| 1445-1500 | <p>Therapeutic Goods Administration (TGA) Good Clinical Practice (GCP) Inspection Program Anastasia Makshakova, Senior Good Clinical Practice (GCP) Inspector – Risk Management Section, Therapeutic Goods Administration, Australian Government Department of Health and Aged Care, Canberra, ACT</p> |
| 1500-1515 | <p>National Clinical Trial Reform Agenda Dr Bernadette Aliprandi-Costa, Director Clinical Trials Policy Section, Health Economics and Research Division, Department of Health and Aged Care, Australian Government</p> |
| 1515-1545 | Questions and discussion |
| 1545 | Seminar close |

Please note: presentation recordings from the live virtual seminar will not be available